Mechanics Bank Trust Department Lowers stake in Baxalta Inc (BXLT)

Baxalta Inc (BXLT) : Mechanics Bank Trust Department reduced its stake in Baxalta Inc by 3.21% during the most recent quarter end. The investment management company now holds a total of 36,228 shares of Baxalta Inc which is valued at $1,499,115 after selling 1,200 shares in Baxalta Inc , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Baxalta Inc makes up approximately 0.58% of Mechanics Bank Trust Department’s portfolio.

Baxalta Inc closed down -0.42 points or -1.02% at $40.8 with 41,40,444 shares getting traded on Wednesday. Post opening the session at $41.03, the shares hit an intraday low of $40.69 and an intraday high of $41.25 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Interactive Financial Advisors sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 16 shares of BXLT which is valued $662.Horizon Kinetics reduced its stake in BXLT by selling 200 shares or 1.41% in the most recent quarter. The Hedge Fund company now holds 14,009 shares of BXLT which is valued at $567,505. Baxalta Inc makes up approx 0.01% of Horizon Kinetics’s portfolio.Coastline Trust Co boosted its stake in BXLT in the latest quarter, The investment management firm added 1,420 additional shares and now holds a total of 33,109 shares of Baxalta Inc which is valued at $1,341,246. Baxalta Inc makes up approx 0.28% of Coastline Trust Co’s portfolio.Bkd Wealth Advisors reduced its stake in BXLT by selling 3,499 shares or 40.6% in the most recent quarter. The Hedge Fund company now holds 5,120 shares of BXLT which is valued at $207,411. Baxalta Inc makes up approx 0.03% of Bkd Wealth Advisors’s portfolio.

On the company’s financial health, Baxalta Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.55. The company had revenue of $1763.00 million for the quarter, compared to analysts expectations of $1712.08 million. The company’s revenue was up 4.8% compared to the same quarter last year.

Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.

Leave a Reply

Baxalta Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxalta Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.